Unlocking the Potential of Polygonatum Odoratum Protein Hydrolysate: Identification, Characterization, and Antidiabetic Activity in HFD/STZ-Induced Type 2 Diabetic Mice

Why It Matters

POP offers a natural, peptide‑based approach to improve glycemic control and oxidative stress, addressing the demand for safe, diet‑derived adjuncts to conventional diabetes therapy.

Key Takeaways

• POP lowers fasting glucose and HbA1c in diabetic mice
• Improves insulin sensitivity and β‑cell morphology
• Reduces serum lipids and hepatic steatosis
• Activates Nrf2 pathway, boosting antioxidant enzymes
• Peptide size (<1.5 kDa) enhances oral bioavailability

Pulse Analysis

The surge in functional‑food research has highlighted bioactive peptides as versatile agents capable of modulating metabolic pathways. While Polygonatum odoratum has long been used in traditional Chinese medicine for its thirst‑quenching and hypoglycemic properties, scientific attention has focused almost exclusively on its polysaccharides. This study bridges that gap by characterizing the protein fraction, revealing a peptide mixture dominated by short sequences rich in leucine and valine—amino acids known to influence insulin signaling and muscle protein synthesis. Such low‑molecular‑weight peptides are more readily absorbed in the gastrointestinal tract, enhancing their potential as oral nutraceuticals.

In the HFD/STZ mouse model, POP demonstrated efficacy comparable to metformin, lowering both fasting and random blood glucose, reducing HbA1c, and improving HOMA‑IR indices. Beyond glycemic control, POP corrected dyslipidemia, attenuated hepatic steatosis, and preserved pancreatic islet architecture. Central to these outcomes was the activation of the Nrf2/Keap1 axis, which up‑regulated antioxidant enzymes (SOD, CAT, GSH‑Px) and reduced oxidative markers such as ROS and MDA. By mitigating oxidative stress—a key driver of insulin resistance and β‑cell dysfunction—POP addresses a root cause of type 2 diabetes rather than merely managing symptoms.

For the nutraceutical industry, POP represents a scalable, plant‑derived functional ingredient that could be incorporated into supplements, fortified foods, or beverage formulations targeting pre‑diabetic and diabetic consumers. However, translation to human use will require rigorous peptide fingerprint standardization, dose‑response studies, and safety assessments under regulatory frameworks. Future research should also explore synergistic effects with gut microbiota and evaluate long‑term outcomes in clinical trials. If these hurdles are navigated, POP could become a cornerstone of diet‑based strategies for metabolic health.